DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Summit Therapeutics stock shot higher this September in response to outstanding clinical-trial results. The company's lead candidate is a cancer therapy that's already approved in China.

Viking Therapeutics Inc (NASDAQ:VKTX) reported positive data from four clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis. The Phase II VENTURE trial for VK2735 ...

End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH ...

Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.